Glioblastoma Multiforme (GBM) has well documented systemic and local immunosuppressive mechanisms to escape immune surveillance and grow. GBM tumor cells as well as the microglia within it have a high PD-L1 surface expression which may make it susceptible to anti-PD-L1 antagonism and ADCC with avelumab therapy. Standard combination temozolomide/radiotherapy is associated with a median survival of 14.6 months and a median progression free survival of 6.9 months.

This is a single center, phase 2, open label study of avelumab 10 mg/kg Q2W for 156 weeks duration in patients receiving standard therapy for newly diagnosed GBM. Thirty patients will be entered into the study within 3 weeks of completing combined radiotherapy/temozolomide.  Here, we report the results of the second interim analysis which was completed when the first 20 patients completed 52 or more  weeks or an end of study visit.